Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.
Kiwuwa-Muyingo S, Walker AS, Oja H, Levin J, Miiro G, Katabira E, Kityo C, Hakim J, Todd J; DART Trial Team. Kiwuwa-Muyingo S, et al. Among authors: hakim j. Trop Med Int Health. 2012 May;17(5):584-94. doi: 10.1111/j.1365-3156.2012.02974.x. Epub 2012 Mar 30. Trop Med Int Health. 2012. PMID: 22463596 Free article. Clinical Trial.
Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
Muyingo SK, Walker AS, Reid A, Munderi P, Gibb DM, Ssali F, Levin J, Katabira E, Gilks C, Todd J; DART Trial Team. Muyingo SK, et al. J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):468-75. doi: 10.1097/QAI.0b013e31817dc3fd. J Acquir Immune Defic Syndr. 2008. PMID: 18614918 Clinical Trial.
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, Darbyshire JH, Grosskurth H, Mugyenyi P, Gibb DM, Gilks CF; DART/NORA trial teams. Munderi P, et al. HIV Med. 2010 May;11(5):334-44. doi: 10.1111/j.1468-1293.2009.00786.x. Epub 2010 Feb 3. HIV Med. 2010. PMID: 20136661 Free article. Clinical Trial.
Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, Katabira E, Grosskurth H, Mugyenyi P, Hakim J, Darbyshire JH, Gibb DM, Babiker AG. Walker AS, et al. Among authors: hakim j. Lancet. 2010 Apr 10;375(9722):1278-86. doi: 10.1016/S0140-6736(10)60057-8. Epub 2010 Mar 27. Lancet. 2010. PMID: 20347483 Free PMC article.
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.
Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S, Hakim J, Munderi P, Chirara M, Ndembi N, Goodall RL, Yirrell DL, Burke A, Gilks CF, Kaleebu P; DART Virology and Trial Team. Lyagoba F, et al. Among authors: hakim j. J Acquir Immune Defic Syndr. 2010 Oct;55(2):277-83. doi: 10.1097/QAI.0b013e3181ea0df8. J Acquir Immune Defic Syndr. 2010. PMID: 20686411
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
Medina Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, Walker AS, Kasirye R, Ssali F, Reid A, Grosskurth H, Babiker AG, Kityo C, Katabira E, Munderi P, Mugyenyi P, Hakim J, Darbyshire J, Gibb DM, Gilks CF; DART Trial Team. Medina Lara A, et al. Among authors: hakim j. PLoS One. 2012;7(4):e33672. doi: 10.1371/journal.pone.0033672. Epub 2012 Apr 24. PLoS One. 2012. PMID: 22545079 Free PMC article. Clinical Trial.
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, Spyer M, Tumukunde D, Nathoo K, Munderi P, Kyomugisha H, Hakim J, Grosskurth H, Gilks CF, Walker AS, Musoke P; DART trial team. Gibb DM, et al. Among authors: hakim j. PLoS Med. 2012;9(5):e1001217. doi: 10.1371/journal.pmed.1001217. Epub 2012 May 15. PLoS Med. 2012. PMID: 22615543 Free PMC article. Clinical Trial.
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirrell D, Kaleebu P; DART Virology Group and Trial Team. Gilks CF, et al. Antivir Ther. 2012;17(7):1363-73. doi: 10.3851/IMP2253. Epub 2012 Jul 19. Antivir Ther. 2012. PMID: 22814125 Clinical Trial.
Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, Katabira E, Gilks CF, Kityo C, Nahirya-Ntege P, Nathoo K, Gibb DM; DART and ARROW trial teams. Walker AS, et al. Among authors: hakim j. Clin Infect Dis. 2012 Dec;55(12):1707-18. doi: 10.1093/cid/cis797. Epub 2012 Sep 12. Clin Infect Dis. 2012. PMID: 22972859 Free PMC article.
541 results